Historical background of AIDS Cure

The scientific assumptions in the application of common hyperthermia in the treatment of HIV-infected and AIDS patients, expressed Weatherburnet al. in the late 80-ies ( "New Sci", 1987, 116, # 1588, 28), (Weatherburn H. Hyperthermia and AIDS-treatment. Br. J Radiol - 1988, v.61, # 729, p.862 - 3.) Yatvin and hypotheses about the use for this purpose a combination of hyperthermia and modifiers of biological membranes (Yatvin MB An approach to AIDS therapy using Hyperthermia and membrane modification. Med. Hypotheses Nov 1988, 27 (3) p.163-5) have been implemented in 1990 the American group of researchers under the leadership of K. Alonso.

In the first clinical experiment K. Alonso, extracorporal arteriovenous overall level of hyperthermia 42 ° C was used in patients with advanced resistant disseminated Kaposi sarcoma and the level of CD4 less than 50. The choice of cases dictated by experience of hyperthermia in oncology. Regression pockets sarcoma was within 48 hours after the procedure and reached a peak for the sixth week, but the full permission of pockets sarcoma did not happen. The level of CD4 increased from 50 to 330, and the activity of reverse transcriptase in the blood decreased by 70%. Publication of the clinical case had great public resonance in the U.S. and immediate negative comments from professionals and power structures that ultimately forced the author to seek the support of the Italian colleagues. (Alonso K. Total body hyperthermia in the treatment of Kaposi's sarcoma in an HIV positive patient. Med. Oncol. Tumor Pharmacoter 1991, 8 (1), p45-7).

In 1991, an Italian clinic Clinica di Cura Citta, Pavia passed Phase I clinical trials of hyperthermia in the treatment of HIV-associated Kaposi sarcoma. In the study, ten patients with Kaposi sarcoma suffered hyperthermia single conversation with temperatures reaching the "core" body 42 ° C for 1 hour. During the 30-day observation after hyperthermia marked a complete and 7 partial remission. Two mixed response was observed in patients with autocrine growth of tumors. For 60 days, two of the 7 patients with partial remission were to show signs of tumor progression. The case of complete remission lasted 120 days. Bullets activity of HIV infection dropped from all responding to treatment. In now case had been observed activation of HIV. Hirsute cellular leukoplakia resolved in all patients. For 8 patients with baseline CD4 less than 60, this figure has not changed. However, two patients with baseline CD4 more than 400, the level of CD 4 has increased dramatically during the treatment. No deaths were observed. (K. Alonso, P. Pontiggia, C. Nardi, A. Sabato, and Curto F. Cuppone. Systemic hyperthermia in the treatment of HIV-related Kaposi's sarcoma. A phase I study. Biomed.Pharmacother. 46 (1): 21 -24, 1992.)

Further investigation of this group of scientists on long-term monitoring of patients with Kaposi sarcoma, endured a total one-time perfusion hyperthermia which was attended by 29 men and 2 women with disseminated Kaposi sarcoma and expressed violations of immunity, gave a very interesting results despite the fact that two of the 31 patients died of secondary complications (arrhythmia, bleeding in the central nervous system). Also mentioned 2 cases DVS.

After 30 days after the procedure, 20 out of 29 patients was complete or partial remission. After 120 days - from 14 out of 29. But after 360 days, with 4 out of 29 patients remained tumor regression, including one complete remission (26 months).